Drug Trial Radar · NCT02232308
Modulation of Heme Oxygenase 1 by Nizatidine and Lisinopril in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Apr 30, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Jul 2014
Primary completion
Sep 2014
Study completion Sep 2014
Sponsor
- Lead sponsor
- Adil BharuchaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Center for Research Resources (NCRR); National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- First posted
- Sep 5, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
To assess if oral nizatidine or lisinopril alone and in combination will increase heme oxygenase 1 (HO-1) protein concentration and activity compared to placebo in healthy subjects.
Conditions
- Gastroparesis
Interventions
NizatidineDrug
Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
LisinoprilDrug
Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
PlaceboDrug
Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in plasma heme oxygenase 1 (HO-1) protein concentrationTime frame: Day 3, Day 10
- Change in Monocyte HO-1 activityTime frame: Day 3, Day 10
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic in Rochester
Rochester, Minnesota
Mayo Clinic
Rochester, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.